Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation

References

• Abercrombie ED, Finlay JM. Techniques in the behavioral and neural sciences. Elsevier Science Ltd, Amsterdam 1991; 7: 253–274
   Google Scholar
• Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998; 56: 747–756
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413–420
   PubMed Web of Science ®Google Scholar
• Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann Neurol 1992; 31: 119–130
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189–193
   PubMed Web of Science ®Google Scholar
• Bodor N, Sloan KB, Higuchi T, Sasahara K. Improved delivery through biological membranes. 4. Prodrugs of L-dopa. J Med Chem 1977; 20(11)1435–1445
   PubMed Web of Science ®Google Scholar
• Cannazza G, Di Stefano A, Mosciatti B, Braghiroli D, Baraldi M, Pinnen F, Sozio P, Benfatti C, Parenti C. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by means of HPLC-EC. J Pharm Biomed Anal 2005; 36: 1079–1084
   PubMed Web of Science ®Google Scholar
• Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR. Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm 1998; 160: 51–59
   Web of Science ®Google Scholar
• Chonn A, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995; 6: 698–708
   PubMed Web of Science ®Google Scholar
• Cooper DR, Marrel C, Van de Waterbeemd H, Testa B, Jenner P, Marsden CD. L-Doppa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987; 39: 627–635
   PubMed Web of Science ®Google Scholar
• Da Prada M, Keller HH, Fieri L, Kettler L, Haefely WE. The pharmacology of Parkinson's disease: Basic aspects and recent advances. Experientia 1984; 40: 1165–1172
   PubMedGoogle Scholar
• Di Stefano A, Mosciatti B, Cingolani GM, Giorgioni G, Ricciutelli M, Cacciatore I, Sozio P, Claudi F. Dimeric L-Dopa derivatives as potential prodrugs. Bioorg Med Chem Lett 2001; 11: 1085–1088
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Carafa M, Sozio P, Pinnen F, Braghiroli D, Orlando G, Cannazza G, Ricciutelli M, Marianecci C, Santucci E. Evaluation of rat striatal L-Dopa and DA concentration after intraperitoneal administration of L-Dopa prodrugs in liposomal formulations. J Control Release 2004; 99: 293–300
   PubMed Web of Science ®Google Scholar
• Dressman JB, Reppas C. In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000; 11(S2)S63–S80
   Google Scholar
• Farghaly AO. Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some non-steroidal anti-inflammatory carboxylic acid drugs. Eur J Med Chem 1998; 33: 123
   Web of Science ®Google Scholar
• Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predictiong in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698–705
   PubMed Web of Science ®Google Scholar
• Gooitzen A, Lameris T, Van den Meiracker AH, Man in't Veld AJ, Boomsma F. Sensitive and specific method for the simultaneous determination of natural and synthetic catecholamines and 3,4-dihydroxyphenylglycol in microdialysis samples. J Chromatogr B 1999; 730: 213–219
   PubMedGoogle Scholar
• Görner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymeric matrix. J Control Release 1999; 57: 259–268
   PubMed Web of Science ®Google Scholar
• Grant DJW, Higuchi T. Solubility and partitioning into water. Solubility behaviour of organic compounds. Wiley, New York 1990; 164–175
   Google Scholar
• Gregoriadis G, Senior J, Wolff B, Kirby C. Fate of liposomes in vivo: Control leading to targeting. Life Sci 1984; 82: 243–266
   Google Scholar
• Gundert-Remy U, Hildebrand R, Stiehl A, Weber E, Zurcher G, Da Prada M. Intestinal absorption of levodopa in man. Eur J Clin Pharmacol 1983; 25: 69–72
   PubMed Web of Science ®Google Scholar
• Ho NFH, Ganesan MG, Weiner ND, Flynn GL. Mechanism of topical delivery of liposomally entrapped drugs. J Control Release 1985; 2: 61–65
   Google Scholar
• Ihara M, Nakajima S, Hisaka A, Tsuchiya Y, Sakuma Y, Suzuki H, Kitani K, Yano M. Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. J Pharm Sci 1990; 79: 703–708
   PubMed Web of Science ®Google Scholar
• Jonkers N, Sarre S, Ebinger G, Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 2001; 108: 559–570
   PubMed Web of Science ®Google Scholar
• Kim S, Scheerer S, Geyer MA, Howell SB. Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes. J Infect Dis 1990; 162: 750–752
   PubMed Web of Science ®Google Scholar
• Koller WC. Handbook of Parkinson's disease2nd ed. USA. Dekker, New York 1992
   Google Scholar
• Mack F, Boenisch H. Dissociation constants and lipophilicity of catecholamines and related compounds. NS Arch Pharmacol 1979; 310: 1–9
   PubMed Web of Science ®Google Scholar
• Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press, Orlando 1986
   Google Scholar
• Santucci E, Carafa M, Coviello T, Murtas E, Riccieri FM, Alhaique F, Modesti A, Modica A. STP Pharm Sci 1996; 6: 29–32
   Google Scholar
• Skinner MK. Intrinsic dissolution rate and solubility studies on josamicin, a macrolide antibiotic. Int J Pharm 1992; 88: 151–158
   Google Scholar
• Streng WH. Experimental procedures and example. Characterization of compounds in solution—theory and practice. Kluver Academic Plenum Publisher, New York 2001; 161–180
   Google Scholar
• Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50: S2–10
   PubMedGoogle Scholar
• Wang H, Lee J, Tsai M, Lu H, Hsu W. Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug. Bioorg Med Chem Lett 1995; 5: 2195–2918
   Web of Science ®Google Scholar
• Yalkowsky SH, Banerjee S. Aqueous solubility: Methods of estimation for organic compounds. Marcel Dekker, New York 1992
   Google Scholar
• Yalkowsky SH, Morzowich W. Drug design, J Ariens. Academic, New York 1980; IX
   Google Scholar
• Yurasov VV, Kucheryanu VG, Kudrin VS, Zhigal'tsev NikushkinEV, IV, Sandalov YG, Kaplun AP, Shvets VI. Effect of long-term parenteral administration of empty and 1-DOPA liposomes on the turnover of dopamine and its metabolites in the striatum of mice with experimental Parkinson's syndrome. Byull Eksp Biol Med 1997; 123: 126–129
   Google Scholar
• Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Ciro-Candiano IC, Gambardella A, Quattrone A. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study. Arch Neurol 2005; 62: 601–605
   PubMed Web of Science ®Google Scholar